Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-man clinical trial of MZE-782 in healthy volunteers

Next Previous
X
Search
Trial Profile

A first-in-man clinical trial of MZE-782 in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MZE 782 (Primary)
  • Indications Renal failure
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics

    • Most Recent Events

    • 09 Oct 2024 New trial record
    • 01 Oct 2024 According to a Maze Therapeutics media release, the first participants have been dosed in this trial. The initial results of this clinical trial, including potential proof of mechanism utilizing these biomarkers, are expected to be provided in the second half of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top